A share price of Ultragenyx Pharmaceutical Inc. [RARE] is currently trading at $53.66, up 6.79%. An important factor to consider is whether the stock is rising or falling in short-term value. The RARE shares have gain 12.10% over the last week, with a monthly amount glided 19.32%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Ultragenyx to Participate at Investor Conferences in March. In a post published today on Yahoo Finance, 44th Annual Cowen Healthcare Conference on March 4.
From an analyst’s perspective:
Ultragenyx Pharmaceutical Inc. [NASDAQ: RARE] stock has seen the most recent analyst activity on December 08, 2023, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $72. On June 06, 2023, upgrade upgraded it’s rating to Outperform and revised its price target to $80 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $114 on April 26, 2023. In a note dated November 03, 2022, Robert W. Baird upgraded an Outperform rating on this stock but restated the target price of $50.
Ultragenyx Pharmaceutical Inc. experienced fluctuations in its stock price throughout the past year between $31.52 and $54.98. Currently, Wall Street analysts expect the stock to reach $113.18 within the next 12 months. Ultragenyx Pharmaceutical Inc. [NASDAQ: RARE] shares were valued at $53.66 at the most recent close of the market. An investor can expect a potential return of 110.92% based on the average RARE price forecast.
Analyzing the RARE fundamentals
Trailing Twelve Months sales for Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE] were 434.25M which represents 23.27% growth. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 51.61 points at the first support level, and at 49.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 54.81, and for the 2nd resistance point, it is at 55.95.
Ultragenyx Pharmaceutical Inc. [RARE] reported earnings per share of -$1.52 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.62/share, meaning a difference of $0.1 and a surprise factor of 6.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$2.23 per share as compared to estimates of -$2.08 per share, a difference of -$0.15 representing a surprise of -7.20%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE] is 2.61. On the other hand, the Quick Ratio is 2.49, and the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 10.17, the price to book ratio is 16.04.
Transactions by insiders
Recent insider trading involved KAKKIS EMIL D, President & CEO, that happened on Feb 07 when 30000.0 shares were sold. President & CEO, KAKKIS EMIL D completed a deal on Dec 29 to sell 30000.0 shares. Meanwhile, CBO & EVP Kassberg Thomas Richard sold 39878.0 shares on Oct 23.
